Structures by: Yan X. C.
Total: 16
Methyl 2-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15FN2O4
Acta Crystallographica Section E (2006) 62, 7 o2689-o2690
a=11.603(2)Å b=9.0170(18)Å c=15.692(3)Å
α=90.00° β=96.90(3)° γ=90.00°
[3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methanol
C9H7ClN2O2
Acta Crystallographica Section E (2006) 62, 7 o3007-o3008
a=7.4280(15)Å b=14.202(3)Å c=8.8050(18)Å
α=90.00° β=106.76(3)° γ=90.00°
4-Methylbenzamidoxime
C8H10N2O
Acta Crystallographica Section E (2006) 62, 7 o3105-o3106
a=6.4220(13)Å b=7.4720(15)Å c=17.181(3)Å
α=79.48(3)° β=82.16(3)° γ=85.45(3)°
Methyl 2-{[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl]methoxy}phenylacetate
C19H18N2O5
Acta Crystallographica Section E (2006) 62, 5 o1839-o1840
a=8.9620(18)Å b=7.9500(16)Å c=25.021(5)Å
α=90.00° β=96.51(3)° γ=90.00°
1-Acetyl-3,3-bis[3-(4-methylphenyl)-1,2,4-oxadiazol-5-ylmethyl]-1H- indol-2(3H)-one
C30H25N5O4
Acta Crystallographica Section E (2006) 62, 6 o2462-o2463
a=15.5510(16)Å b=6.9695(14)Å c=25.220(2)Å
α=90.00° β=103.46(3)° γ=90.00°
Methyl 2-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15BrN2O4
Acta Crystallographica Section E (2006) 62, 3 o1131-o1132
a=20.011(4)Å b=9.643(2)Å c=18.089(4)Å
α=90.00° β=98.33(3)° γ=90.00°
Methyl 2-(2-{1-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]-2- (dimethylamino)vinyloxy}phenyl)-3-(dimethylamino)acrylate
C24H25BrN4O4
Acta Crystallographica Section E (2006) 62, 8 o3467-o3468
a=15.479(3)Å b=8.5690(17)Å c=17.919(4)Å
α=90.00° β=98.37(3)° γ=90.00°
1-{[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]methyl}-4-[(2,6- dimethylphenyl)aminocarbonylmethyl]piperazine
C23H26BrN5O2
Acta Crystallographica Section E (2006) 62, 8 o3465-o3466
a=7.2000(14)Å b=9.5300(19)Å c=33.089(7)Å
α=90.00° β=94.71(3)° γ=90.00°
1-Acetyl-3,3-bis[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]-1H-indolin-2(3H)-one
C30H25N5O4
Acta Crystallographica Section E (2006) 62, 3 o917-o918
a=11.680(2)Å b=12.234(2)Å c=18.396(4)Å
α=90.00° β=93.85(3)° γ=90.00°
[3-(2-Methylphenyl)-1,2,4-oxadiazol-5-yl]methanol
C10H10N2O2
Acta Crystallographica Section E (2006) 62, 4 o1302-o1303
a=7.529(2)Å b=14.307(3)Å c=8.799(3)Å
α=90.00° β=106.39(3)° γ=90.00°
3-Methoxybenzamide oxime
C8H10N2O2
Acta Crystallographica Section E (2006) 62, 10 o4243-o4244
a=6.8630(14)Å b=18.910(4)Å c=12.893(3)Å
α=90.00° β=101.77(3)° γ=90.00°
[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methanol
C9H7ClN2O2
Acta Crystallographica Section E (2006) 62, 10 o4226-o4227
a=27.789(2)Å b=4.0141(5)Å c=21.4570(15)Å
α=90.00° β=127.56(3)° γ=90.00°
Methyl {2-[3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenyl}acetate
C18H14Cl2N2O4
Acta Crystallographica Section E (2006) 62, 10 o4405-o4406
a=7.4910(15)Å b=15.613(3)Å c=15.100(3)Å
α=90.00° β=90.59(3)° γ=90.00°
1-Acetyl-3,3-bis[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-ylmethyl]indolin-2-one
C30H25N5O6
Acta Crystallographica Section E (2006) 62, 10 o4640-o4641
a=8.6300(17)Å b=11.866(2)Å c=14.616(3)Å
α=108.95(3)° β=99.02(3)° γ=101.17(3)°
5-chloromethyl-3-(2,4-dichlorophenyl)-1,2,4-oxadiazole
C9H5Cl3N2O
Acta Crystallographica Section E (2006) 62, 10 o4715-o4716
a=7.9010(16)Å b=14.987(3)Å c=9.7400(19)Å
α=90.00° β=113.20(3)° γ=90.00°
2-amino-4-methylpyridinium nitrate
C6H9N2,NO3
Acta Crystallographica Section C (2013) 69, 1 61-65
a=8.4150(7)Å b=12.8669(11)Å c=15.2441(14)Å
α=90.00° β=90.00° γ=90.00°